BlackRock’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.7B | Buy |
23,969,517
+217,528
| +0.9% | +$101M | 0.19% | 89 |
|
|
2025
Q4 | $10.8B | Buy |
23,751,989
+1,498,942
| +7% | +$646M | 0.18% | 92 |
|
|
2025
Q3 | $8.72B | Buy |
22,253,047
+381,102
| +2% | +$159M | 0.15% | 107 |
|
|
2025
Q2 | $9.74B | Buy |
21,871,945
+89,012
| +0.4% | +$41M | 0.19% | 94 |
|
|
2025
Q1 | $10.6B | Sell |
21,782,933
-42,537
| -0.2% | -$19.8M | 0.22% | 77 |
|
|
2024
Q4 | $8.79B | Buy |
21,825,470
+37,924
| +0.2% | +$17.6M | 0.18% | 91 |
|
|
2024
Q3 | $10.1B | Buy |
21,787,546
+475,302
| +2% | +$228M | 0.21% | 78 |
|
|
2024
Q2 | $9.99B | Sell |
21,312,244
-648,443
| -3% | -$281M | 0.23% | 72 |
|
|
2024
Q1 | $9.18B | Buy |
21,960,687
+79,484
| +0.4% | +$33.6M | 0.21% | 77 |
|
|
2023
Q4 | $8.9B | Sell |
21,881,203
-704,023
| -3% | -$260M | 0.23% | 71 |
|
|
2023
Q3 | $7.85B | Sell |
22,585,226
-235,200
| -1% | -$82.3M | 0.23% | 72 |
|
|
2023
Q2 | $8.03B | Sell |
22,820,426
-1,086,177
| -5% | -$366M | 0.22% | 73 |
|
|
2023
Q1 | $7.53B | Sell |
23,906,603
-334,834
| -1% | -$100M | 0.22% | 82 |
|
|
2022
Q4 | $7B | Sell |
24,241,437
-1,001,623
| -4% | -$305M | 0.22% | 84 |
|
|
2022
Q3 | $7.31B | Buy |
25,243,060
+105,908
| +0.4% | +$30.5M | 0.25% | 71 |
|
|
2022
Q2 | $7.08B | Buy |
25,137,152
+1,220,898
| +5% | +$327M | 0.23% | 77 |
|
|
2022
Q1 | $6.24B | Sell |
23,916,254
-28,677
| -0.1% | -$6.81M | 0.17% | 102 |
|
|
2021
Q4 | $5.26B | Buy |
23,944,931
+397,036
| +2% | +$77.2M | 0.13% | 130 |
|
|
2021
Q3 | $4.27B | Buy |
23,547,895
+187,806
| +0.8% | +$36.7M | 0.12% | 142 |
|
|
2021
Q2 | $4.71B | Sell |
23,360,089
-884,024
| -4% | -$185M | 0.13% | 132 |
|
|
2021
Q1 | $5.21B | Sell |
24,244,113
-24,782
| -0.1% | -$5.44M | 0.15% | 112 |
|
|
2020
Q4 | $5.74B | Sell |
24,268,895
-906,646
| -4% | -$208M | 0.18% | 94 |
|
|
2020
Q3 | $6.85B | Sell |
25,175,541
-332,357
| -1% | -$91.7M | 0.25% | 67 |
|
|
2020
Q2 | $7.41B | Buy |
25,507,898
+3,181,850
| +14% | +$863M | 0.3% | 60 |
|
|
2020
Q1 | $5.31B | Buy |
22,326,048
+1,209,227
| +6% | +$277M | 0.26% | 70 |
|
|
2019
Q4 | $4.62B | Buy |
21,116,821
+42,700
| +0.2% | +$8.64M | 0.18% | 105 |
|
|
2019
Q3 | $3.57B | Buy |
21,074,121
+365,452
| +2% | +$64.7M | 0.15% | 125 |
|
|
2019
Q2 | $3.8B | Buy |
20,708,669
+532,371
| +3% | +$93.1M | 0.16% | 108 |
|
|
2019
Q1 | $3.71B | Buy |
20,176,298
+568,488
| +3% | +$105M | 0.17% | 107 |
|
|
2018
Q4 | $3.25B | Sell |
19,607,810
-328,033
| -2% | -$56.8M | 0.16% | 109 |
|
|
2018
Q3 | $3.84B | Buy |
19,935,843
+625,328
| +3% | +$111M | 0.17% | 110 |
|
|
2018
Q2 | $3.28B | Sell |
19,310,515
-577,530
| -3% | -$89.5M | 0.15% | 121 |
|
|
2018
Q1 | $3.24B | Buy |
19,888,045
+478,972
| +2% | +$78.2M | 0.15% | 125 |
|
|
2017
Q4 | $2.91B | Sell |
19,409,073
-326,848
| -2% | -$48.4M | 0.14% | 138 |
|
|
2017
Q3 | $3B | Buy |
19,735,921
+329,940
| +2% | +$49.7M | 0.15% | 132 |
|
|
2017
Q2 | $2.5B | Buy |
19,405,981
+159,601
| +0.8% | +$19.2M | 0.13% | 152 |
|
|
2017
Q1 | $2.1B | Buy |
19,246,380
+18,558,874
| +2,699% | +$1.63B | 0.12% | 177 |
|
|
2016
Q4 | $50.6M | Sell |
687,506
-59,727
| -8% | -$4.86M | 0.07% | 311 |
|
|
2016
Q3 | $65.2M | Buy |
747,233
+7,843
| +1% | +$741K | 0.09% | 243 |
|
|
2016
Q2 | $63.6M | Buy |
739,390
+60,800
| +9% | +$5.25M | 0.1% | 234 |
|
|
2016
Q1 | $53.9M | Sell |
678,590
-34,032
| -5% | -$3.08M | 0.09% | 261 |
|
|
2015
Q4 | $89.7M | Buy |
712,622
+23,209
| +3% | +$2.8M | 0.13% | 178 |
|
|
2015
Q3 | $71.8M | Sell |
689,413
-69,169
| -9% | -$8.89M | 0.11% | 213 |
|
|
2015
Q2 | $93.7M | Sell |
758,582
-195,798
| -21% | -$24.7M | 0.14% | 176 |
|
|
2015
Q1 | $113M | Buy |
954,380
+81,587
| +9% | +$9.78M | 0.16% | 150 |
|
|
2014
Q4 | $104M | Buy |
872,793
+198,308
| +29% | +$22.3M | 0.15% | 152 |
|
|
2014
Q3 | $75.8M | Buy |
674,485
+126,558
| +23% | +$12M | 0.11% | 194 |
|
|
2014
Q2 | $51.9M | Sell |
547,927
-71,465
| -12% | -$5.01M | 0.08% | 278 |
|
|
2014
Q1 | $43.8M | Sell |
619,392
-73,058
| -11% | -$5.79M | 0.07% | 288 |
|
|
2013
Q4 | $51.5M | Buy |
692,450
+130,085
| +23% | +$9.06M | 0.08% | 249 |
|
|
2013
Q3 | $42.6M | Buy |
562,365
+431,507
| +330% | +$34.3M | 0.08% | 263 |
|
|
2013
Q2 | $10.5M | Buy |
+130,858
| New | +$9.64M | 0.02% | 585 |
|
Other funds holding VRTX
VCM
VPM
BlackRock's VRTX Position: Q1 2026 in Review
BlackRock increased its Vertex Pharmaceuticals (VRTX) stake by 0.92% in Q1 2026, buying an estimated $101M and bringing the position to 23,969,517 shares worth $10.7B. The position accounts for 0.19% of the portfolio, ranked #89.
BlackRock first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.8B in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- BlackRock held 23,969,517 shares of Vertex Pharmaceuticals worth $10.7B as of Q1 2026.
- BlackRock bought 217,528 Vertex Pharmaceuticals shares in Q1 2026, an estimated $101M.
- Vertex Pharmaceuticals made up 0.19% of BlackRock's portfolio in Q1 2026, its #89 holding.
- BlackRock first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- BlackRock's Vertex Pharmaceuticals position peaked at $10.8B in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.